INTRODUCTION
============

The differentiation of myoblasts into myotubes is important for the development of muscle-specific structures and contractile function ([@b2-molce-40-9-667]; [@b7-molce-40-9-667]). Myoblast differentiation is regulated by two families of transcription factors ([@b35-molce-40-9-667]; [@b47-molce-40-9-667]), namely, the basic helix-loop-helix (bHLH) myogenic regulatory factors (MRFs) that consist of MyoD (Myf-3) ([@b9-molce-40-9-667]), Myogenin (Myf-1) ([@b13-molce-40-9-667]), Myf5 ([@b4-molce-40-9-667]) and Mrf4 (Myf-6) ([@b5-molce-40-9-667]), and myocyte enhancer factor 2 (MEF2) factors that contain MEF2A, B, C and D ([@b35-molce-40-9-667]). All MRFs contain a conserved basic domain for DNA binding and a bHLH domain necessary for heterodimerization with ubiquitous bHLH E-proteins ([@b47-molce-40-9-667]). Among the MRFs, Myf5 and MyoD are required for myogenic lineage determination and myoblast proliferation ([@b25-molce-40-9-667]; [@b38-molce-40-9-667]; [@b45-molce-40-9-667]; [@b46-molce-40-9-667]; [@b54-molce-40-9-667]), whereas Myogenin and Mrf4 play critical roles in the fusion of myoblasts into myotubes and terminal differentiation ([@b21-molce-40-9-667], [@b36-molce-40-9-667]). The ability of MyoD to determine myogenic lineage depends on its functions in chromatin remodeling at silent loci and in the transcriptional activation of muscle genes ([@b3-molce-40-9-667]; [@b17-molce-40-9-667]). The MEF2 family, which consists of four vertebrate MEF2 family members, has been found to have muscle-specific DNA-binding activity when myoblasts differentiate into myotubes ([@b18-molce-40-9-667]; [@b39-molce-40-9-667]; [@b44-molce-40-9-667]). MEF2A, B, and D are ubiquitously expressed, whereas MEF2C is selectively expressed in skeletal muscle, brain and spleen ([@b32-molce-40-9-667]; [@b33-molce-40-9-667]; [@b41-molce-40-9-667]; [@b56-molce-40-9-667]). The role of MEF2C during myogenic differentiation has been well studied because of its abundant expression in skeletal muscle ([@b32-molce-40-9-667]; [@b33-molce-40-9-667]). MyoD is able to bind and target promoters of *MEF2C* and *MYOG* (Myogenin) in order to promote muscle specific gene expression, resulting in myotube formation ([@b6-molce-40-9-667]; [@b12-molce-40-9-667]; [@b14-molce-40-9-667]). On the other hand, the interactions between MRFs/MEF2 and transcriptional co-repressors/co-activators may also determine muscle differentiation. Representative chromatin remodeling enzymes include lysine acetyltransferase and lysine methyltransferase ([@b10-molce-40-9-667]; [@b19-molce-40-9-667]; [@b42-molce-40-9-667]). Among the histone modifications these enzymes initiate, histone deacetylation, H3-K9 demethylation and H3-K27 trimethylation are closely associated with transcriptional suppression (heterochromatin) ([@b8-molce-40-9-667]; [@b10-molce-40-9-667]; [@b19-molce-40-9-667]; [@b40-molce-40-9-667]). Elimination of theses transcriptional corepressors from MRFs and MEF2 induces the activation of muscle specific promoters ([@b1-molce-40-9-667]; [@b34-molce-40-9-667]). In contrast, H3-R8 demethylation, H3-R17 demethylation, and H3-K4 trimethylation are related to transcriptional activation ([@b19-molce-40-9-667]). In addition, H3-K9 and H3-K14 histone acetylation is associated with the augmented expression of genes ([@b23-molce-40-9-667]; [@b48-molce-40-9-667]).

As mentioned above, the lysine modification of histones is one of the major mechanisms that regulates gene expression. In the present study, we searched for factors related to histone acetylation and methylation that may regulate muscle differentiation. PCR-based screening analysis showed that histone deacetylase 11 (HDAC11) would be a highly influential histone modification factor involved in the regulation of myoblast differentiation. HDAC enzymes remove acetyl groups from lysine residues within histones H3 and H4 of the nucleosome. In addition, HDAC enzymes can directly bind to MyoD and MEF2, and target muscle-specific gene promoters as well as their own promoters ([@b22-molce-40-9-667]; [@b28-molce-40-9-667]; [@b29-molce-40-9-667]; [@b30-molce-40-9-667]; [@b31-molce-40-9-667]). HDAC11 has recently been identified as a unique member of the class IV HDAC, consisting of only a catalytic domain ([@b16-molce-40-9-667]; [@b20-molce-40-9-667]; [@b51-molce-40-9-667]). However, the relationship between HDAC11 and myoblast differentiation has not been established. Therefore, in this study, we investigated the effect of HDAC11 on myoblast differentiation using wild-type HDAC11 and its catalytically inactive mutant (H142/143A) ([@b43-molce-40-9-667]; [@b49-molce-40-9-667]; [@b50-molce-40-9-667]). Our novel findings of the role of HDAC11 in myoblast differentiation provide an improved understanding of the factors regulating myoblast differentiation.

MATERIALS AND METHODS
=====================

Cell culture
------------

Murine C2C12 myoblasts were obtained from the American Type Culture Collection (ATCC). Cells were cultured in a DMEM high-glucose medium (Gibco-Invitrogen) supplemented with 15% heat-inactivated fetal bovine serum (FBS) and 1% antibiotic-antimycotic solution, as a growth medium (GM), at 37°C in a humidified atmosphere of 5% CO~2~. To initiate myogenic differentiation, C2C12 myoblasts with 50--70% confluence were grown in a DMEM culture medium containing 2% horse serum and 1% antibiotic-antimycotic solution as a differentiation medium (DM). The differentiation medium was changed every day until the indicated times.

Quantitative PCR (qPCR) analysis
--------------------------------

Total RNA was isolated from undifferentiated or differentiated C2C12 cell lines using the RNeasy® Lipid Tissue Mini Kit (Qiagen, USA). We used 2 μg of total RNA to generate cDNA with the MMLV Reverse Transcriptase and random primers (Promega). The cDNA was analyzed by quantitative PCR using a SYBR green PCR kit and a C1000 Touch™ Thermal Cycler (Bio-Rad). All data were normalized to ribosomal L32 expression.

Western blot analysis
---------------------

Cells were lysed in a protein lysis buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 50 mM NaF, 5 mM β-glycero-phosphate, 1 mM sodium orthovanadate, 1 mM DTT, and a protease inhibitor cocktail (Roche). Western blot analyses was performed on 5--30 μg whole-cell extracts. Proteins were separated by electrophoresis on SDS-polyacrylamide gels and transferred to polyvinylidene difluoride (PVDF) membranes (Pall Corporation). Membranes were blocked with 5% skim milk and probed with primary antibodies. Anti-HDAC11 was obtained from Abcam. Antibodies against myosin heavy chain (MHC) and M2-Flag were purchased from Sigma-Aldrich. Antibodies against HSP90, MyoD1, MEF2C, and Myogenin were obtained from Santa Cruz Biotechnology. Antisera against phospho-AMPK, AMPK, phospho-AKT and AKT were from Cell Signaling Technology. The specific signals were amplified by horseradish peroxidase-conjugated secondary anti-rabbit IgG or anti-mouse IgG (Santa Cruz Biotechnology) and were visualized using an enhanced chemiluminescence system (BD Biosciences).

Generation of stable cell lines
-------------------------------

The coding sequence of HDAC11 was amplified from mouse cDNA using PCR and cloned into the pRetroX-IRES-ZsGreen1 vector with an N-terminal FLAG tag (Clontech). The catalytically inactive HDAC11 mutant (H142/143A) was generated using QuikChange site-directed mutagenesis kit (Agilent). To generate retroviruses expressing GFP only, HDAC11 and HDAC11 (H142/143A) mutant constructs were individually co-transfected into GP2-293 cells with pVSV-G (Clontech) using Lipofectamine 2000 (Gibco-Invitrogen). At 48--72 h after transfection, the media with retrovirus-containing supernatant were collected and passed through a 0.45 μm filter. C2C12 myoblasts were infected with retroviruses expressing GFP control, HDAC11 or its mutant in the presence of polybrene (8μg/ml). Infected C2C12 myoblasts were enriched by determining the degree of GFP expression using a FACSAria cell sorter (BD Biosciences). At differentiation day 5, stable cell lines were confirmed by Western blot assay and qPCR analysis.

Immunocytochemistry (ICC)
-------------------------

Cells were fixed with 4% paraformaldehyde for 20 min at room temperature. Cells were incubated in 0.1% Triton X-100 for 15 min at room temperature for permeabilization. Cells were then incubated with blocking buffer (Roche) in a 0.1% Triton X-100 for 1 h at room temperature, followed by overnight incubation at 4°C with the primary antibody against MHC. Cells were then incubated with the secondary antibody (Santa Cruz). Cellular nuclei were stained with DAPI solution (Invitrogen), and images were captured with a Leica DM IL LED microscope with a Leica DFC 450C.

Luciferase reporter assay
-------------------------

C2C12 stable cell lines were maintained with DMEM growth media (GM). For transfection, cells were seeded in triplicate in 24-well plates at 1 × 10^5^ cells per well. Trans IT®-LT1 transfection reagents (Mirus Bio) were used in accordance with the manufacturer's instructions. Each transfection was performed with 300 ng of reporter constructs fused with the luciferase gene (pGL4.12-MEF2C and pGL4.12-4RTK promoter), 50 ng of a CMV-β-galactosidase plasmid, and 5 ng of expression plasmid for pcDNA3-flag-MyoD. Total cell lysates were prepared 48 h after transfection, and promoter activities were assessed using the Dual-Luciferase reporter assay system (Promega) ([@b26-molce-40-9-667]).

Immunoprecipitation (IP)
------------------------

C2C12 stable cells were washed twice with ice-cold PBS and lysed in a protein lysis buffer. The resulting cell lysates were incubated with anti-acetyl-lysine agarose (EMD Millipore) overnight at 4°C. The beads were subsequently washed three times each with protein lysis buffer, followed by suspension in the sample buffer. The eluted proteins were resolved by 10%SDS-polyacrylamide (PAGE) gel electrophoresis and analyzed by Western blotting with anti-annexinA1 (Abcam).

Chromatin immunoprecipitation (ChIP)
------------------------------------

Cross-linking of protein complexes, nuclear isolation, and immunoprecipitation assays in C2C12 cells expressing wild-type or mutant HDAC11 were performed as previously described ([@b37-molce-40-9-667]). Cells were treated with 1% formaldehyde for 20 min to cross-link histones to DNA, and were washed twice in PBS. Crosslinked cells were then lysed with cell lysis buffer (0.1% NP40, 10 mM KCl, 1.5 mM MgCl~2~, 1 mM DTT, 25 mM HEPES pH 7.8, and a protease inhibitor cocktail). Subsequently, cell lysates were centrifuged at 5,000 rpm for 2 min at 4°C, and the supernatants were removed. The pellets were lysed with a nuclear lysis buffer (1% Triton X-100, 140 mM NaCl, 1 mM EDTA, 0.1% Na-deoxycholate, 0.1% SDS, 50 mM HEPES pH7.9 and a protease inhibitor cocktail). The nuclear lysates were sonicated at 20% output (Sonics VC505) and then centrifuged at 13,000 rpm for 10 min at 4°C. The supernatants were collected as chromatin samples. For each immunoprecipitation reaction, the supernatant proteins were immunoprecipitated with anti-histone H3K9 antibodies (Santa Cruz Biotechnology). Anti-rabbit IgG was used as a negative control. Precipitated DNA fragments were analyzed by PCR using primers against relevant mouse promoters.

Statistical analysis
--------------------

Experimental data are shown as the mean ± standard deviation (SD) or ± standard error of the mean (SEM), as indicated in the figure legends. Comparisons of different groups were performed using two-tailed unpaired Student's *t*-tests. In all statistical comparisons, *P* values \< 0.05 were considered statistically significant.

RESULTS
=======

HDAC11 expression is markedly and consistently increased during mouse skeletal myoblast differentiation
-------------------------------------------------------------------------------------------------------

Recently, it has been reported that the PTM of histone proteins affect the expression levels of myogenic genes during myoblast differentiation ([@b10-molce-40-9-667]; [@b19-molce-40-9-667]; [@b42-molce-40-9-667]). To access the relationship between histone modification and myoblast differentiation, we focused on enzymes involved in histone acetylation and methylation, two major PTMs of histones for regulating gene transcription. We observed changes in mRNA expression levels after differentiation compared with before differentiation in C2C12 myoblasts using qPCR analysis. Among the enzymes that demonstrated *P* values \< 0.01, those whose correlation with myogenic differentiation is not well known and are novel enough to investigate are shown in [Table 1](#t1-molce-40-9-667){ref-type="table"}. While several genes satisfy both *P* value (\<0.01) and fold-change (2-fold) criteria, the change in mRNA levels of HDAC11 was strikingly increased more than 100 times after differentiation compared with before differentiation of C2C12 myoblasts ([Table 1](#t1-molce-40-9-667){ref-type="table"}). Changes in mRNA and protein levels of HDAC11 were further confirmed ([Figs. 1A and 1B](#f1-molce-40-9-667){ref-type="fig"}). As shown in [Fig. 1B](#f1-molce-40-9-667){ref-type="fig"}, HDAC11 mRNA expression gradually increased with the induction of myogenic differentiation markers (MyoD, Myogenin, and MEF2C) during myoblast differentiation.

Stable expression of HDAC11 impedes C2C12 myoblast differentiation
------------------------------------------------------------------

Our results obtained from screening analysis indicated the possibility of HDAC11 as a highly influential histone modification factor involved in the regulation of myoblast differentiation. To investigate the effect of HDAC11 on myoblast differentiation, we generated C2C12 stable cell lines expressing flag-tagged HDAC11 or retrovirus control. Expression levels of HDAC11 in C2C12 stable cell lines were confirmed both at mRNA and protein levels ([Fig. 2A](#f2-molce-40-9-667){ref-type="fig"}). The expression of HDAC11 suppressed C2C12 myoblast differentiation, as assessed by MHC staining ([Fig. 2B](#f2-molce-40-9-667){ref-type="fig"}), and markedly reduced the fusion index of myocytes ([Fig. 2C](#f2-molce-40-9-667){ref-type="fig"}). This was concomitant with a decrease in mRNA and protein levels of the muscle-specific transcription factors, MEF2C and Myogenin ([Figs. 2D and 2E](#f2-molce-40-9-667){ref-type="fig"}). MyoD protein levels were slightly decreased by HDAC11 expression, whereas its mRNA levels did not change ([Figs. 2D and 2E](#f2-molce-40-9-667){ref-type="fig"}). Among other MEF2 family members, expression levels of MEF2A and D were not influenced by HDAC11 expression ([Fig. 2D](#f2-molce-40-9-667){ref-type="fig"}), and MEF2B gene expression was not detected (data not shown). Further, to test whether abnormal differentiation of skeletal muscle cells by HDAC11 can affect its function, we evaluated the phosphorylation levels of AKT and AMPK, two main regulators in the glucose uptake signaling pathway. As shown in [Fig. 2F](#f2-molce-40-9-667){ref-type="fig"}, HDAC11 expression reduced the active phosphorylated forms of AKT and AMPK in skeletal muscle cells.

The deacetylase activity of HDAC11 is involved in the suppression of myoblast differentiation
---------------------------------------------------------------------------------------------

To further investigate if the enzymatic activity of HDAC11 is associated with myoblast differentiation, we generated C2C12 stable cell lines expressing flag-tagged wild-type and mutant (H142A/H143A) HDAC11. It has been previously reported that substitution of histidine to alanine on amino acids 142 and 143 of HDACs can block their deacetylase activity ([@b43-molce-40-9-667]; [@b49-molce-40-9-667]; [@b50-molce-40-9-667]). In contrast to HDAC11 expression, expression of the catalytically inactive mutant of HDAC11 did not suppress myogenic differentiation ([Fig. 3A](#f3-molce-40-9-667){ref-type="fig"}), and it was confirmed by the measurement of the fusion myogenic index ([Fig. 3B](#f3-molce-40-9-667){ref-type="fig"}). Consistent with these results, mRNA and protein expression of transcription factors associated with myoblast differentiation such as MEF2C and Myogenin were also suppressed by wild-type HDAC11 expression, but not that of the catalytically inactive mutant ([Figs. 3C and 3D](#f3-molce-40-9-667){ref-type="fig"}). In addition, HDAC11 expression reduced the AMPK phosphorylation levels, whereas its deacetylase inactive mutant did not influence the phosphorylation state of AMPK ([Fig. 3E](#f3-molce-40-9-667){ref-type="fig"}).

HDAC11 suppresses myoblast differentiation in a MyoD-dependent manner
---------------------------------------------------------------------

MyoD is one of the transcription factors that regulates the transcription levels of MEF2C and Myogenin by directly binding to their promoters. This prompted us to investigate the effects of HDAC11 as a histone deacetylase on the MyoD-dependent promoter activities of MEF2C and Myogenin. MyoD-induced MEF2C promoter activity was decreased in the C2C12 cell line expressing wild-type HDAC11, but not in its enzymatically inactive mutant (H142A/H143A) cell line ([Fig. 4A](#f4-molce-40-9-667){ref-type="fig"}). Next, to investigate the effect of HDAC11 on My-oD-dependent Myogenin transcription, we used a MyoD-dependent promoter 4RTK luciferase construct, which contains four tandem E-box transcription factor binding sites from the muscle creatine kinase (MCK) promoter ([@b53-molce-40-9-667]). MyoD regulates the expression of Myogenin by binding to the E-box region in the *MYOG* (Myogenin) promoter. As shown in [Fig. 4B](#f4-molce-40-9-667){ref-type="fig"}, MyoD-induced luciferase activity of 4RTK was decreased in the C2C12-HDAC11 cell line, but not in its enzymatically inactive mutant cell line. These data suggest that HDAC11 suppresses transcription of the MEF2C and Myogenin in a MyoD-dependent manner in order to inhibit myogenic differentiation. To further examine whether HDAC11 influences the acetylation state near the E-boxes, the MyoD binding site, of the *MEF2C* and *MYOG* promoters ([@b30-molce-40-9-667]; [@b52-molce-40-9-667]), we performed chromatin immunoprecipitation (ChIP) assays in C2C12 cells expressing wild-type or catalytically inactive HDAC11 using an anti-histone H3K9 antibody ([@b27-molce-40-9-667]). Histone acetylation near the E-boxes of the *MEF2C* and *MYOG* promoters was reduced by HDAC11, but not by the catalytically inactive HDAC11 mutant ([Figs. 4C and 4D](#f4-molce-40-9-667){ref-type="fig"}). As previously reported, the binding of HDAC to MyoD may inhibit MyoD-dependent myogenic gene transcription ([@b30-molce-40-9-667]). Therefore, to further elucidate the relationship between HDAC11 and MyoD during myogenic differentiation, we measured the interaction between the two molecules. As shown in [Fig. 5A](#f5-molce-40-9-667){ref-type="fig"}, HDAC11 physically interacted with MyoD, and wild type HDAC11, but not the inactive HDAC11 mutant, strongly bound to endogenous MyoD in a time-dependent manner during myoblast differentiation ([Fig. 5B](#f5-molce-40-9-667){ref-type="fig"}). These data suggest that the deacetylase activity of HDAC11 is essential for MyoD binding, followed by the regulation of MyoD-dependent transcription.

DISCUSSION
==========

HDAC11 was discovered in 2002, and classified as a class IV HDAC, where it was the only member. However, the functional and physiological role of HDAC11 has remained largely unknown until now. Here we show for the first time that HDAC11 can regulate myogenic differentiation. Our findings demonstrated that HDAC11 was significantly up-regulated during myoblast differentiation. Ectopic expression of wild-type HDAC11 induced the suppression of myoblast differentiation, whereas the catalytically inactive mutant did not affect myoblast differentiation. Although the effect of HDAC11 depletion in C2C12 cells was not shown in this study, it was thought that disruption of proper differentiation by HDAC11 depletion in C2C12 cells would excessively promote myogenic differentiation. Further, we investigated whether HDAC11-suppressed myoblast differentiation could affect muscle function by observing phosphorylation levels of AMPK and AKT ([Figs. 2F](#f2-molce-40-9-667){ref-type="fig"} and [3E](#f3-molce-40-9-667){ref-type="fig"}). Actually, it has been reported that AMPK and AKT could affect transcriptional activity of MyoD ([@b15-molce-40-9-667]; [@b55-molce-40-9-667]). Therefore, it was possible that reduced phosphorylation levels of AMPK and AKT in C2C12 stable cell line expressing HDAC11 might influence transcriptional activity of MyoD. However, the interaction of HDAC11 with MyoD increased in a time-dependent manner during myogenic differentiation, although the ectopic expression of HDAC11 slightly decreased the expression of endogenous MyoD protein ([Fig. 5](#f5-molce-40-9-667){ref-type="fig"}). These data strongly supported that inhibition of MyoD-dependent transcription was most directly driven by HDAC11 at least in this model.

MyoD controls myoblast proliferation and myogenic lineage progression. It is intimately involved in muscle differentiation by regulating the transcription of muscle-specific genes such as MEF2C and Myogenin ([@b3-molce-40-9-667]; [@b6-molce-40-9-667]; [@b12-molce-40-9-667]; [@b14-molce-40-9-667]; [@b17-molce-40-9-667]). MyoD can directly bind to the promoter regions of *MEF2C* and *MYOG*, and MyoD-induced muscle gene expression can be mediated by chromatin remodeling ([@b3-molce-40-9-667]; [@b17-molce-40-9-667]). Therefore, we hypothesized that inhibition of myogenic differentiation by HDAC11 would be associated with histone deacetylation at the promoter regions of MyoD target genes such as *MEF2C* and *MYOG*. As expected, HDAC11 lowered the promoter activities of *MEF2C* and *MYOG*, and reduced histone acetylation levels near the MyoD binding sites of the *MEF2C* and *MYOG* promoters ([Fig. 4](#f4-molce-40-9-667){ref-type="fig"}). Under physiological conditions, it was thought that HDAC11 would function as a negative regulator, finely controlling muscle differentiation ([Fig. 6](#f6-molce-40-9-667){ref-type="fig"}).

The mechanism for HDACs that underlie the regulation of gene expression is not limited to histone modification. Recently, it was reported that HDACs can regulate target gene expression by modulating mRNA stability ([@b24-molce-40-9-667]). Thus, we also investigated whether HDAC11 can affect the stability of MyoD, MEF2C, and Myogenin mRNA. However, no effects of HDAC11 on mRNA stability were observed (data not shown). To gain further insight into the mechanism of HDAC11-induced inhibition of myoblast differentiation, we attempted to find non-histone targets of HDAC11 by Western blot analysis using an anti-acetyl-lysine antibody after 2-dimesional gel electrophoresis. We obtained several candidates such as annexin A1, voltage-dependent anion-selective channel protein 1, enolase 1B, and guanine nucleotide-binding protein subunit β-1 ([Supplementary Fig. 1A](#s1-molce-40-9-667){ref-type="supplementary-material"}). In the case of annexin A1, validation using Western blot analysis showed that our data were reliable ([Supplementary Fig. 1B](#s1-molce-40-9-667){ref-type="supplementary-material"}). These efforts strongly indicated that HDAC11 may also target non-histone proteins as substrates for deacetylation. However, more detailed studies are necessary to clarify the effects of HDAC11 on non-histone targets during myoblast differentiation.

In addition to HDAC11, our screening analysis detected several undescribed enzymes, including SRC-1, PCAF, JHDM1D, and KDM5B that may be associated with myoblast differentiation ([Table 1](#t1-molce-40-9-667){ref-type="table"}). Further investigation of these enzymes is warranted to better understand the regulation of myogenic differentiation by histone modification.

Taken together, our novel findings revealed that HDAC11 impedes myoblast differentiation in a MyoD-dependent manner via modulation of histone acetylation in the *MEF2C* and *MYOG* promoters. In addition, other enzymes demonstrating expression changes during myoblast differentiation, and several non-histone candidate target proteins of HDAC11, were also discovered. These data should provide further understanding of the regulation of myoblast differentiation.

Supplementary data
==================
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Note: [Supplementary information](#s1-molce-40-9-667){ref-type="supplementary-material"} is available on the Molecules and Cells website ([www.molcells.org](www.molcells.org)).

![HDAC11 is up-regulated during myogenic differentiation.\
C2C12 myoblasts were differentiated for the indicated periods. (A) Western blot analysis showing protein expression level of HDAC11 during myoblast differentiation. (B) qPCR analysis showing mRNA levels of HDAC11 and myogenic differentiation markers (MyoD, Myogenin, and MEF2C) during myoblast differentiation.](molce-40-9-667f1){#f1-molce-40-9-667}

![The ectopic expression of HDAC11 inhibits myogenic differentiation.\
C2C12 myoblasts were stably infected with retroviruses expressing control vector (CV) or HDAC11. C2C12 stable cells were differentiated for 4 days. (A) The expression levels of HDAC11 in stable cell lines were determined by western blot and qPCR analysis. (B) Myotube formations were determined by ICC using an anti-myosin heavy chain (MHC). (C) The fusion index was calculated as the ratio of the nuclei in MHC-positive tubes verses the total number of nuclei. Data represent the mean from three different spots ± SEM (\*\*\**P* \< 0.005). (D, E) The mRNA and protein levels of myogenic differentiation markers in C2C12 cells with stable expression of HDAC11 were determined by qPCR analysis and western blot analysis. (F) Differentiated myotubes were treated with 500 μM AICAR (an analog of AMP that is capable of stimulating AMPK activity) for 2 h or insulin for 15 min. Phosphorylation levels of AMPK and AKT were detected by western blot analysis. Data in (D) represent the mean ± SD (\**P* \< 0.05, \*\**P* \< 0.005).](molce-40-9-667f2){#f2-molce-40-9-667}

![The enzymatic activity of HDAC11 is involved in suppression of myogenic differentiation.\
C2C12 stable cells expressing control vector (CV), HDAC11, or HDAC11 (H142/143A) mutant were differentiated for 5 days. (A) Multinucleated myotubes were characterized by immunofluorescence using anti-myosin heavy chain (MHC). (B) The fusion index was calculated as the ratio of the nuclei in MHC-positive tubes verses the total number of nuclei. Data represent the mean from three different spots ± SEM (\*\*\**P* \< 0.005). (C, D) Cells were differentiated for the indicated times. The mRNA and protein levels of myogenic markers were determined by qPCR analysis and western blot analysis. (E) Differentiated myotubes were treated with 500 μM AICAR for 2 h. The phosphorylation level of AMPK was detected by western blot analysis. Data in (C) represent the mean ± SD (\**P* \< 0.05, \*\**P* \< 0.005, \*\*\**P* \< 0.0005). (CV, control vector; H11, HDAC11; Mut, HDAC11 (H142/143A) mutant)](molce-40-9-667f3){#f3-molce-40-9-667}

![HDAC11 decreases histone acetylation at the promoter regions of *MEF2C* and *MYOG* and impedes transcription of *MEF2C* and *MYOG* in a MyoD-dependent manner.\
(A, B) C2C12 myoblasts expressing HDAC11 or the HDAC11 (H142/143A) mutant were co-transfected with 300 ng of pGL4-luciferase constructs (MEF2C or 4RTK) and 5 ng of vector expressing MyoD for 48 h. (C, D) The chromatin immunoprecipitation experiment at day 3 after differentiation was performed to check the effect of HDAC11 on the acetylated histone H3K9 at the promoter region of *MEF2C* and *MYOG*. Data in (A--D) represent the mean ± SD (\**P* \< 0.05, \*\**P* \< 0.005, \*\*\**P* \< 0.0005). (cv, control vector; mut, HDAC11 (H142/143A) mutant)](molce-40-9-667f4){#f4-molce-40-9-667}

![HDAC11 directly interacts with MyoD.\
(A) 293T cells were co-transfected with Flag-HDAC11 and HA-MyoD for 48 h. Extracts from transfected cells were immunoprecipitated with anti-Flag or anti-HA, followed by western blot using anti-Flag and anti-HA. (B) C2C12 cells expressing CV control, HDAC11 or HDAC11 (H142/143A) mutant were differentiated for the indicated times. Cell lysates were immunoprecipitated with anti-Flag, followed by Western blot using anti-Flag and anti-MyoD. (CV, control vector; H11, HDAC11; Mut, HDAC11 (H142/143A) mutant)](molce-40-9-667f5){#f5-molce-40-9-667}

![A proposed model for HDAC11-mediated suppression of myoblast differentiation.\
The expression level of HDAC11 was gradually increased during the process of myogenic differentiation. Elevated expression of HDAC11 down-regulated the levels of histone acetylation at promoter regions of *MEF2C* and *MYOG*, and consequently suppressed myoblast differentiation in a MyoD-dependent manner. HDAC11 could also target non-histone factors as substrates for deacetylation during myoblast differentiation. In conclusion, HDAC11 would be essential for proper myogenic differentiation, and its regulatory mechanism would provide important clues for fine regulation of myogenic differentiation.](molce-40-9-667f6){#f6-molce-40-9-667}

###### 

The list of enzymes showing significant changes in gene expression levels during myoblast differentiation

  Modification   Name of gene        Function            Fold change (4 day/0 day)                           *p-*value
  -------------- ------------------- ------------------- --------------------------------------------------- ---------------------------------------------------
  Acetylation    PCAF                Acetyltransferase   3.02                                                [\*\*](#tfn2-molce-40-9-667){ref-type="table-fn"}
  SRC-1          Acetyltransferase   8.42                [\*\*](#tfn2-molce-40-9-667){ref-type="table-fn"}   
  HDAC11         Deacetylase         107.57              [\*\*](#tfn2-molce-40-9-667){ref-type="table-fn"}   
  Methylation    MLL2                Methyltransferase   2.69                                                [\*](#tfn1-molce-40-9-667){ref-type="table-fn"}
  MLL3           Methyltransferase   2.45                [\*](#tfn1-molce-40-9-667){ref-type="table-fn"}     
  PRDM9          Methyltransferase   2.33                [\*](#tfn1-molce-40-9-667){ref-type="table-fn"}     
  ASH1           Methyltransferase   2.04                [\*\*](#tfn2-molce-40-9-667){ref-type="table-fn"}   
  SETD7          Methyltransferase   2.32                [\*](#tfn1-molce-40-9-667){ref-type="table-fn"}     
  JHDM1D         Demethylase         8.83                [\*](#tfn1-molce-40-9-667){ref-type="table-fn"}     
  KDM5B          Demethyalse         5.77                [\*](#tfn1-molce-40-9-667){ref-type="table-fn"}     

*P* \< 0.01,

*P* \< 0.005

[^1]: These authors contributed equally to this work.
